Skin autofluorescence of advanced glycation end-products relates to new cardiovascular events in type 2 diabetes: A longitudinal observational study
Authors' conclusion
SAF of advanced glycation end-products was related to a higher incidence of later CVE in patients with T2DM.
Study context
- Population
- Patients hospitalized for uncontrolled and/or complicated T2D between 2009 and 2017
- Participants
- 504 patients
- Exposure
- Patients with vs without later CVE; Skin autofluorescence (SAF) above vs below median
- CVEn = 69
- Outcome
- CVE (MI, stroke, revascularization procedures or cardiovascular death) in relation to baseline SAF of advanced glycation end-products
- Follow-up
- From admission to December 2020
Methodological detailslongitudinal observational, multivariable Cox regression
- Longitudinal observational
- Multivariable Cox regression
Main finding
As reported in the abstract
Baseline SAF · 54 months of follow-up
P = 0.002
- Patients with a CVE
- 69 (13.7%)
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| CVE-free survival, SAF above vs below whole-population median | log-rank: P = 0.002 |
| CVE-free survival, macroangiopathy-free subpopulation, SAF above vs below subpopulation median | log-rank: P = 0.016 |
Original publication
Skin autofluorescence of advanced glycation end-products relates to new cardiovascular events in type 2 diabetes: A longitudinal observational study. Diabetes Metab. Published 11 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →